Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22686964 | 0.93 | S1PR2 (1.00) | S1PR2MAPT | |
| SCHEMBL14068487 | 0.93 | S1PR2 (0.75) | S1PR2MAPT | |
| SCHEMBL22686945 | 0.92 | S1PR2 (1.00) | S1PR2MAPT | |
| SCHEMBL3303619 | 0.92 | S1PR2 (0.87) | S1PR2MAPT | |
| SCHEMBL22693557 | 0.91 | S1PR2 (0.82) | S1PR2MAPT | |
| SCHEMBL22693533 | 0.91 | S1PR2 (1.00) | S1PR2MAPT | |
| SCHEMBL3315010 | 0.91 | S1PR2 (0.86) | S1PR2MAPT | |
| SCHEMBL22693619 | 0.91 | S1PR2 (0.85) | S1PR2MAPT | |
| SCHEMBL22693559 | 0.90 | S1PR2 (0.84) | S1PR2MAPT | |
| SCHEMBL22686954 | 0.90 | S1PR2 (1.00) | S1PR2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012164103-A2 | BLOCKERS OF THE NOGO-A S1PR PATHWAY FOR THE TREATMENT OF DISEASES CHARACTERIZED BY NEURONAL DAMAGE AND LACK OF SUBSEQUENT REPAIR | Universität Zürich (CH) | 2012-12-06 | — | — | WO | claimed |
| US-20200369626-A1 | COMPOSITIONS OF SPHINGOSINE-1-PHOSPHATE RECEPTOR 2 (S1PR2) BINDING AGENTS AND USES THEREOF | WASHINGTON UNIVERSITY (US) | 2020-11-26 | — | — | US | disclosed |
| EP-3298014-A1 | S1PR2 ANTAGONISTS AND USES THEREFOR | Dalhousie University (CA) | 2018-03-28 | — | — | EP | disclosed |
| WO-2016191872-A1 | S1PR2 ANTAGONISTS AND USES THEREFOR | DALHOUSIE UNIVERSITY (CA) | 2016-12-08 | — | — | WO | disclosed |
| US-20140187550-A1 | BICYCLIC ORGANIC COMPOUNDS SUITABLE FOR THE TREATMENT OF INFLAMMATORY OR ALLERGIC CONDITIONS | NOVARTIS AG (CH) | 2014-07-03 | — | — | US | disclosed |
| US-20140187550-A1 | BICYCLIC ORGANIC COMPOUNDS SUITABLE FOR THE TREATMENT OF INFLAMMATORY OR ALLERGIC CONDITIONS | NOVARTIS AG (CH) | 2014-07-03 | — | — | US | disclosed |
| US-20140187550-A1 | BICYCLIC ORGANIC COMPOUNDS SUITABLE FOR THE TREATMENT OF INFLAMMATORY OR ALLERGIC CONDITIONS | NOVARTIS AG (CH) | 2014-07-03 | — | — | US | disclosed |
| US-8633211-B2 | Bicyclic organic compounds suitable for the treatment of inflammatory or allergic conditions | NOVARTIS AG (CH) | 2014-01-21 | — | — | US | disclosed |
| US-8633211-B2 | Bicyclic organic compounds suitable for the treatment of inflammatory or allergic conditions | NOVARTIS AG (CH) | 2014-01-21 | — | — | US | disclosed |
| US-8633211-B2 | Bicyclic organic compounds suitable for the treatment of inflammatory or allergic conditions | NOVARTIS AG (CH) | 2014-01-21 | — | — | US | disclosed |
| WO-2012164103-A2 | BLOCKERS OF THE NOGO-A S1PR PATHWAY FOR THE TREATMENT OF DISEASES CHARACTERIZED BY NEURONAL DAMAGE AND LACK OF SUBSEQUENT REPAIR | Universität Zürich (CH) | 2012-12-06 | — | — | WO | disclosed |
| WO-2012164103-A2 | BLOCKERS OF THE NOGO-A S1PR PATHWAY FOR THE TREATMENT OF DISEASES CHARACTERIZED BY NEURONAL DAMAGE AND LACK OF SUBSEQUENT REPAIR | Universität Zürich (CH) | 2012-12-06 | — | — | WO | disclosed |
| US-20100113774-A1 | BICYCLIC ORGANIC COMPOUNDS SUITABLE FOR THE TREATMENT OF INFLAMMATORY OR ALLERGIC CONDITIONS | NOVARTIS AG (CH) | 2010-05-06 | — | — | US | disclosed |
| US-20100113774-A1 | BICYCLIC ORGANIC COMPOUNDS SUITABLE FOR THE TREATMENT OF INFLAMMATORY OR ALLERGIC CONDITIONS | NOVARTIS AG (CH) | 2010-05-06 | — | — | US | disclosed |
| EP-2132186-A1 | BICYCLIC ORGANIC COMPOUNDS SUITABLE FOR THE TREATMENT OF INFLAMMATORY OR ALLERGIC CONDITIONS | Novartis AG (CH) | 2009-12-16 | — | — | EP | disclosed |
| WO-2008107436-A1 | BICYCLIC ORGANIC COMPOUNDS SUITABLE FOR THE TREATMENT OF INFLAMMATORY OR ALLERGIC CONDITIONS | NOVARTIS AG (CH) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113774-A1 | BICYCLIC ORGANIC COMPOUNDS SUITABLE FOR THE TREATMENT OF INFLAMMATORY OR ALLERGIC CONDITIONS | S1PR3, S1PR1, S1PR2 | S1PR2 3/4885MAPT 3853/4885 |
| US-20140187550-A1 | BICYCLIC ORGANIC COMPOUNDS SUITABLE FOR THE TREATMENT OF INFLAMMATORY OR ALLERGIC CONDITIONS | S1PR3, S1PR1, S1PR2 | S1PR2 3/4885MAPT 4020/4885 |
| US-20200369626-A1 | COMPOSITIONS OF SPHINGOSINE-1-PHOSPHATE RECEPTOR 2 (S1PR2) BINDING AGENTS AND USES THEREOF | S1PR2, S1PR1, S1PR3 | S1PR2 1/4885MAPT 1482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.